iBio, Inc. has introduced cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics, for preclinical and clinical stage programs. The operation is housed in the company’s 135,000 sq.-ft. manufacturing facility in Bryan, TX.

The sterile liquid fill-finish operation will incorporate in-line labeling, allowing serialization of vials as they are filled. Initial capacity supports 100 – 2,500 vials runs, with plans to expand to 15,000.

"Providing Fill-Finish services is a natural extension of iBio’s FastPharming biologics CDMO capabilities," said Robert Kay, chief executive officer. "Given our ability to quickly deliver GMP and research quantities of active pharmaceutical ingredient (API), the addition of the fill-finish operation completes our rapid, end-to-end service offering."

"We understand the needs of early stage companies, who often face moving targets for their timelines and support requirements," said Nicolas Taquet, Vice President, Biopharmaceutical Manufacturing. "It is often problematic trying to identify available capacity for high-quality, small volume filling. We’re now in position to fill that need for our clients."

iBio will be presenting more details on its 5mL vial and 100mL bottle filling services at BIO 2019 in Philadelphia, PA, June 3-6.

Register as Visitor to CPhI China 2019 NOW!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.